Design, Synthesis, Biological Evaluation and Docking Study of Novel Quinazoline Derivatives As EGFR-TK Inhibitors

References

• Housman G , BylerS , HeerbothSet al. Drug resistance in cancer: an overview. Cancers6, 1769–1792 (2014).
   PubMed Web of Science ®Google Scholar
• Shawver LK , SlamonD , UllrichA. Smart drugs: tyrosine kinase inhibitors in cancer therap. Cancer Cell.1, 117–123 (2002).
   PubMed Web of Science ®Google Scholar
• Traxler P , BoldG , BuchdungerEet al. Tyrosine kinase inhibitors: from rational design to clinical trials. Med. Res. Rev.21, 499–512 (2001).
   PubMed Web of Science ®Google Scholar
• Aaronson SA . Growth factors and cancer. Science254, 1146–1153 (1991).
   PubMed Web of Science ®Google Scholar
• Prenzel N , FischerOM , StreitSet al. The epidermal growth factor receptor family as a central element for cellular signal transduction and diversification. Endocr-Relat. Cancer 8, 11–31 (2001).
   PubMed Web of Science ®Google Scholar
• Mendelsohn J , BaselgaJ. Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer. J. Clin. Oncol.21, 2787–2799 (2003).
   PubMed Web of Science ®Google Scholar
• Chandrika PM , RamRao AR , NarsaiahBBet al. Quinazoline derivatives with potent anti-inflammatory and anti-allergic activities. Int. J. Chem. Sci.6, 1119–1146 (2008).
   Google Scholar
• Kung PP , CasperMD , CookKLet al. Structure-activity relationships of novel 2-substituted quinazoline antibacterial agents. J. Med. Chem.42, 4705–4713 (1999).
   PubMed Web of Science ®Google Scholar
• Malamas MS , MillenJ. Quinazolineacetic acids and related analogues as aldose reductase inhibitors. J. Med. Chem.34, 1492–1503 (1991).
   PubMed Web of Science ®Google Scholar
• Cheng JB , ArcherRL , ChapinDS. Structure-activity relationship of quinazolinedione inhibitors of calcium-independent phosphodiesterase. J. Med. Chem.34, 624–628 (1991).
   PubMed Web of Science ®Google Scholar
• Fry DW , KrakerAJ , MichaelA. A specific inhibitor of the epidermal growth factor receptor tyrosine kinase. Science265, 1093–1095 (1994).
   PubMed Web of Science ®Google Scholar
• Cohen MH , WilliamsGA , SridharaRet al. FDA drug approval summary: gefitinib (ZD1839) (Iressa) tablets. Oncologist8, 303–306 (2003).
   PubMed Web of Science ®Google Scholar
• Dowell J , MinnaJD , KirkpatrickP. Erlotinib hydrochloride. Nat. Rev. Drug Discov.4, 14–15 (2005).
   Web of Science ®Google Scholar
• Nelson MH , DolderCR. Lapatinib: a novel dual tyrosine kinase inhibitor with activity in solid tumors. Ann. Pharmacother.40, 261–269 (2006).
   PubMed Web of Science ®Google Scholar
• Cecilia Trinks EA , SeverinssonB , HolmlundAet al. The pan-ErbB tyrosine kinase inhibitor canertinib induces caspase-mediated cell death in human T-cell leukemia (Jurkat) cells. Biochem. Biophys. Res. Commun.410, 422–427 (2011).
   PubMed Web of Science ®Google Scholar
• Stamos J , SliwkowskiMX , EigenbrotCet al. Structure of the epidermal growth factor receptor kinase domain alone and in complex with a 4-anilinoquinazoline inhibitor. J. Biol. Chem.277, 46265–46272 (2002).
   PubMed Web of Science ®Google Scholar
• Milik SN , KamalA , LasheenDSet al. Surmounting the resistance against EGFR inhibitors through the development of thieno[2,3-d]pyrimidine-based dual EGFR/HER2 inhibitors. Eur. J. Med. Chem.155, 316–336 (2018).
   PubMed Web of Science ®Google Scholar
• Ouyang Y , ZouW , PengLet al. Design, synthesis, antiproliferative activity and docking studies of quinazoline derivatives bearing 2,3-dihydro-indole or 1,2,3,4-tetrahydroquinoline as potential EGFR inhibitors. Eur J. Med. Chem. 154, 29–43 (2018).
   PubMed Web of Science ®Google Scholar
• Rao GW , XuGJ , WangJet al. Synthesis, antitumor evaluation and docking study of novel 4-anilinoquinazoline derivatives as potential epidermal growth factor receptor (EGFR) inhibitors. Chem. Med. Chem.8, 928–933 (2013).
   Google Scholar
• Chen L , ZhangY , LiuJet al. Novel 4-arylaminoquinazoline derivatives with (E)-propen-1-yl moiety as potent EGFR inhibitors with enhanced antiproliferative activities against tumor cells. Eur. J. Med. Chem.138, 689–697 (2017).
   PubMed Web of Science ®Google Scholar
• Zhang Y , ZhangY , LiuJet al. Synthesis and in vitro biological evaluation of novel quinazoline derivatives. Bioorg. Med. Chem. Lett. 27, 1584–1587 (2017).
   PubMed Web of Science ®Google Scholar
• Wood ER , TruesdaleAT , McDonaldOBet al. A unique structure for epidermal growth factor receptor bound to GW572016 (Lapatinib): relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cells. Canc. Res.64, 6652–6659 (2004).
   PubMed Web of Science ®Google Scholar
• Hu Y , ShiL , SuYet al. A fluorescent light-up aggregation-induced emission probe for screening gefitinib-sensitive non-small cell lung carcinoma. Biomed. Sci.5, 792–799 (2017).
   Google Scholar
• Cheng X , MerzKH , VatterSet al. Identification of a water-soluble indirubin derivative as potent inhibitor of insulin-like growth factor 1 receptor through structural modification of the parent natural molecule. J. Med. Chem.60, 4949–4962 (2017).
   PubMed Web of Science ®Google Scholar
• Nieddu V , PinnaG , MarchesiIet al. Synthesis and antineoplastic evaluation of novel unsymmetrical 1,3,4-oxadiazoles. J. Med. Chem.59, 10451–10469 (2016).
   PubMed Web of Science ®Google Scholar
• Yu SY , LiuHF , WangSPet al. Evidence of securin-mediated resistance to gefitinib-induced apoptosis in human cancer cells. Chem. Biol. Interact.203, 412–422 (2013).
   PubMed Web of Science ®Google Scholar
• Wu G , RobertsonDH , BrooksCL3rdet al. Detailed analysis of grid-based molecular docking: a case study of CDOCKER-A CHARMm-based MD docking algorithm. J. Comput. Chem.24, 1549–1562 (2003).
   PubMed Web of Science ®Google Scholar